Influence of needle size for subcutaneous insulin administration on metabolic control and patient acceptance
DOI:
https://doi.org/10.1002/edn.77Keywords:
Insulin administration, injection devices, needle lengthAbstract
AbstractAim: To investigate whether the length of the needle used for intermittent subcutaneous insulin administration affects metabolic control, injection-related side effects and patient preference.
Method: In a crossover study, 68 patients with type 1 and type 2 diabetes, body mass index ≥ 18 kg/m2, were randomised into two groups; 52 patients completed the trial. Patients in group A used a 5 mm needle for their insulin injections over a period of 13 weeks, then switched to a longer needle (8 or 12 mm). Patients in group B used the needles in reverse order. Patients were re-assessed at 26 weeks. Primary endpoints were insulin doses, and frequency and severity of hypoglycaemic events. Secondary endpoints were patient preference and frequency of injection-related bruising, bleeding, insulin leakage and pain.
Results: A total of 52 patients completed the study. No change in the mean glycosylated haemoglobin (HbA1c) level was found in group B (baseline, 7.41%; 13 weeks, 7.38%; 26 weeks, 7.34%), whereas a small but significant rise in mean HbA1c level was observed in group A after returning to the longer needle (baseline, 7.67%; 13 weeks, 7.65%; 26 weeks, 7.87%: p<0.05). There were no significant changes in the amount of insulin injected, frequency or severity of hypoglycaemic events or insulin leakage in either group. The 5 mm needle was associated with a significant decrease in bleeding, bruising and pain (p<0.05). Most patients (86%) showed a preference for the 5 mm needle (p<0.05).
Conclusion: For insulin injection, a 5 mm needle length is associated with unchanged HbA1c levels, unchanged frequency or severity of hypoglycaemic events and less discomfort for patients compared with 8 or 12 mm needles. The use of 5 mm needles is as safe as 8 or 12 mm needles. Further research is advisable involving thin and obese patients using 5 mm needles, in order for shorter needles to be recommended as standard practice.
Downloads
References
Thow JC, Johnson AB, Fulcher G, et aL. Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Diabet Med 1990; 7: 600–602.
Thow JC, Coulthard A, Home PD. Insulin injection site tissue depths and localisation of a simulated insulin bolus using a novel air con-trast ultrasonographic technique in insulin treated diabetic subjects. Diabet Med 1992; 9: 915–920.
Bantle JR Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type 1 diabetes subjects. Diabetes Care 1993; 16: 1592–1597.
Engstrom L, Bergman A. A new injection technique for insulin treat-ment, simpler to use and as effective? Scand J Caring Sci 1993; 7: 57–59.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
Stratton IM, Adler Al, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000; 321: 405–412.
American Diabetes Association. Insulin administration. Diabetes Care 2004; 27 (Suppl 1): S106—S109.
de Meijer PH, Lutterman JA, Van't Laar A. The absorption of subcutaneously injected insulin. Neth J Med 1989; 34: 210–227.
Frid A, Ostman J, Linde B. Hypoglycemia risk during exercise after intramuscular injection of insulin in thigh in IDDM. Diabetes Care 1990; 13: 473–477.
Henriksen JE, Vaag A, Hansen IR, et aL. Absorption of NPH (isophane) insulin in resting diabetic patients: evidence for subcutaneous injection in the thigh as the preferred site. Diab Med 1991; 8: 453–457.
Vaag A, Handberg A, Lauritzen M, et aL. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care 1990; 13:74–76.
Thow JC, Home PD. Insulin injection technique BMJ 1990; 301: 3–4.
Cryer PE. Hypoglycemia. Patho-physiology, Diagnosis and Treatment. New York: Oxford University Press, 1997; 96.
Strauss K, Gols De H, et al. A pan-European epidemiological study of insulin injection technique in patients with diabetes. Pract Diabetes Int 2002; 19: 71–76.
van Doom LG, Albeda A, Lytzen L. Insulin leakage and pain perception with NovoFine, 6 mm and NovoFine, 12 mm needle lengths in patients with type 1 and type 2 diabetes (Abstract). Diabetic Medicine 1998; 15: S50.
Strauss K, Hannet I, McGonigle JM, et aL. Ultra-short (5 mm) insulin needles: trial results and clinical recommendations. Pract Diabetes Int 1999; 16: 218–222.
Arendt-Nielsen L, Egekvist H. Bjerring P. Pain perception following controlled needle insertion: the impact of needle gauge. Diabetes 2005; 54 (Suppl): 420–P.
Hanas R, Lytzen L, Ludvigsson J. Thinner needles do not influence injection pain, insulin leakage or bleeding in children and adolescents with type 1 diabetes. Pediatr Diabetes 2000; 1: 142–149.
McGuire DB. Measuring Pain. In: Instruments for Clinical Health-Care Research. Frank-Stromborg M, Olsen SJ (eds). Sudbury, Massachusetts: Jones and Bartlett Publishers, 1997; 535.
Soon DKW, de la Rena A, Teng CH, et al. More rapid pharmacokinetics and pharmacodynamics of insulin lispro delivered intradermally via a new microneedle system. (ADA meeting 2006, Abstract 426 P).
Heinemann L, Pettis RJ, Hompesch M, et al. Intra-dermal insulin lispro application with a new microneedle delivery system led to a substantially more rapid insulin absorption than subcutaneous injection (ADA meeting 2006, Abstract 108-OR).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2007 Copyright © 2007 FEND
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
